These findings support further evaluation of GLIS3 as a biomarker for risk stratification and provide a rationale for biomarker-guided targeting of the GLIS3-TGFBR3-Hedgehog axis in STAD. This evidence concerns the gene GLIS3 and gastric adenocarcinoma.